Deal Details
Vor Bio Prices $116 Million Public Offering and Concurrent Private Placement
Summary
Vor Biopharma Inc. (“Vor Bio”) (NASDAQ:VOR), recently priced an underwritten public offering and a private placement, with combined gross proceeds of approximately $115.8 million. In the underwritten public offering, Vor Bio has agreed to sell 15,302,267 shares of its common stock at a price of $4.30 per share. Gross proceeds from the offering were approximately $65.8 million. In addition, Vor Bio has agreed to sell 11,627,907 shares of its common stock in a concurrent private placement at a price of $4.30 per share to one or more affiliates of RA Capital Management, Vor Bio’s largest stockholder, for aggregate gross proceeds of approximately $50.0 million.
Baird acted as a co-lead manager on the public offering.
About
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. Vor Biopharma Inc. is headquartered in Cambridge, Massachusetts.CONTACT US TO LEARN MORE
- Date
- December 2022
- Company
- Vor Biopharma Inc.
- Transaction
- Equity Capital Markets
- Sectors
- Healthcare
- Verticals
-
Biotechnology & Pharmaceuticals
- Target Geography
- North America
Share
